Business Context and Reporting Period
Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2025
Reporting Period: Event-based report regarding a material definitive agreement entered into on June 16, 2025.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a strategic operational agreement.
Material Changes and Events
- Material Definitive Agreement: On June 16, 2025, the Company entered into a Statement of Work (SOW) with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO).
- Scope of Agreement: Cellipont will provide technology transfer and current good manufacturing practice (cGMP) manufacturing services.
- Target Product: The agreement supports the scale-up and production of MT-601, the Company's lead Multi-Antigen Recognizing (MAR)-T cell therapy.
- Timeline: The SOW covers a nine-month period for the transfer of manufacturing and testing processes and procedures.
- Study Support: The manufacturing activities are intended to support the Company's APOLLO study.
Guidance, Outlook, and Management Commentary
The filing references a press release issued on June 17, 2025, announcing the SOW. No specific financial guidance, forward-looking revenue projections, or management commentary regarding risks or contingencies is provided within the text of this 8-K filing.
Investor Verification Checklist
- Verify the specific financial terms and payment milestones of the SOW with Cellipont Bioservices, which are not detailed in this filing.
- Review the attached Exhibit 99.1 (Press Release) for additional details on the APOLLO study timeline and manufacturing capacity.
- Confirm the current cash position of Marker Therapeutics to assess the ability to fund the nine-month technology transfer and manufacturing scale-up.
- Monitor subsequent filings for updates on the status of the MT-601 manufacturing transfer and APOLLO study enrollment.